Aurinia Commences Tender Offer to Acquire Kezar Life Sciences for $6.955 Cash Plus Contingent Value Rights

summarizeSummary

Aurinia Pharma U.S., Inc. has formally commenced its tender offer to acquire all outstanding shares of Kezar Life Sciences, Inc. for $6.955 per share in cash and one nontransferable Contingent Value Right (CVR) per share, following the definitive merger agreement announced on March 30, 2026.

check_boxKey Events

• Tender Offer Commencement

  Aurinia Pharma U.S., Inc. formally launched its tender offer to acquire all outstanding shares of Kezar Life Sciences, Inc. on April 13, 2026.

• Offer Price Structure

  Shareholders will receive $6.955 per share in cash and one nontransferable Contingent Value Right (CVR) per share. The CVRs have a probability-weighted estimated value of $1.11-$2.32, but payments are not guaranteed.

• Board Recommendation

  Kezar's Board of Directors unanimously recommended that shareholders accept the offer and tender their shares.

• Transaction Timeline

  The tender offer is set to expire on May 8, 2026, and will be followed by a merger that will result in Kezar's delisting from Nasdaq.

auto_awesomeAnalysis

This SC TO-T filing marks the formal launch of the tender offer by Aurinia to acquire all outstanding shares of Kezar Life Sciences, Inc., following the definitive merger agreement announced on March 30, 2026. The offer provides shareholders with a fixed cash component of $6.955 per share and one nontransferable Contingent Value Right (CVR) per share. While the CVRs offer potential additional payments based on future events related to Kezar's legacy assets and net cash, with a probability-weighted estimate of $1.11-$2.32 per CVR, the filing explicitly warns that shareholders should base their decision solely on the cash amount as CVR payments are not guaranteed. The Kezar Board unanimously recommended the offer, providing a definitive exit for shareholders of a company that recently underwent significant restructuring and workforce reduction. The transaction is expected to lead to Kezar's delisting from Nasdaq.